Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex
- PMID: 41354720
- DOI: 10.1038/s41467-025-66534-w
Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex
Abstract
Most cancers upregulate the telomere lengthening enzyme telomerase to achieve unlimited cell division. How chemotherapeutic nucleoside 6-thio-2'-deoxyguanosine (6-thio-dG) targets telomerase to inhibit telomere maintenance in cancer cells and tumors was unclear. Here, we demonstrate that telomerase insertion of 6-thio-dGTP prevents synthesis of additional telomeric repeats but does not disrupt telomerase binding to telomeres. Specifically, 6-thio-dG inhibits telomere extension after telomerase translocates along its product DNA to reposition the template, inducing a non-productive complex rather than enzyme dissociation. Furthermore, we provide direct evidence that 6-thio-dG treatment inhibits telomere synthesis by telomerase in cancer cells. In agreement, telomerase-expressing cancer cells harboring critically short telomeres are more sensitive to 6-thio-dG and show a greater induction of telomere losses compared to cancer cells with long telomere reserves. Our studies reveal that telomere length and telomerase status determine 6-thio-dG sensitivity and uncover the molecular mechanism by which 6-thio-dG selectively inhibits telomerase synthesis of telomeric DNA.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Update of
-
Chemotherapeutic 6-thio-2'-deoxyguanosine selectively targets and inhibits telomerase by inducing a non-productive telomere-bound telomerase complex.bioRxiv [Preprint]. 2025 Jun 27:2025.02.05.636339. doi: 10.1101/2025.02.05.636339. bioRxiv. 2025. Update in: Nat Commun. 2025 Dec 7. doi: 10.1038/s41467-025-66534-w. PMID: 39975053 Free PMC article. Updated. Preprint.
References
-
- de Lange, T. Shelterin-mediated telomere protection. Annu. Rev. Genet. 52, 223–247 (2018).
-
- d’Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003).
-
- Jaskelioff, M. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102–106 (2011).
-
- Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549–1556 (2003).
-
- Shay, J. W. & Wright, W. E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26, 867–874 (2005).
Grants and funding
- R35ES030396/U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS)
- R01CA207342/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- F32CA275287/Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention)
- R01GM095850/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- R35GM153235/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
LinkOut - more resources
Full Text Sources
